NewcelX AG (NCEL)
NewcelX AG (NASDAQ: NCEL) is a common stock listing on the NASDAQ exchange tied to NewcelX Ltd., a biotechnology company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Founded in 2008, the company is headquartered in Zurich, Switzerland. Its work centers on advancing therapeutic approaches in areas where treatment options remain limited, reflecting its position within the healthcare and biotechnology sector.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NCEL
|
$3.08
|
1.5% Upside
|
Fair
|
$23
|
657.6% Upside
|
Bargain
|
Fair
|
0.0%
|
December 2, 2026
|
2.8x
|
17.535 M
|
16.842 M
|
2.2%
|
46.5%
|
-214.7
|
-9,170.9%
|
